Ionis Pharmaceuticals IONS shares rallied 8.9% in the last trading session to close at $27.77. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at ...

Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer attacks and improved disease control, according to a poster presented here ...

Learn more about whether Alvotech or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price ...

Natixis Advisors LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 32.1% during ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.